These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 21195878)

  • 1. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
    Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
    Dahle J; Krogh C; Melhus KB; Borrebaek J; Larsen RH; Kvinnsland Y
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):886-95. PubMed ID: 19679402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
    Abbas N; Bruland ØS; Brevik EM; Dahle J
    Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
    Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ
    Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
    Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
    PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
    Akabani G; Carlin S; Welsh P; Zalutsky MR
    Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.
    Abbas N; Heyerdahl H; Bruland ØS; Brevik EM; Dahle J
    Curr Radiopharm; 2013 Jun; 6(2):78-86. PubMed ID: 23551110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
    Heyerdahl H; Røe K; Brevik EM; Dahle J
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):153-9. PubMed ID: 23790511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
    Dahle J; Borrebaek J; Jonasdottir TJ; Hjelmerud AK; Melhus KB; Bruland ØS; Press OW; Larsen RH
    Blood; 2007 Sep; 110(6):2049-56. PubMed ID: 17536011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
    Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
    Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
    Dahle J; Borrebaek J; Melhus KB; Bruland OS; Salberg G; Olsen DR; Larsen RH
    Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells.
    Hoang B; Reilly RM; Allen C
    Biomacromolecules; 2012 Feb; 13(2):455-65. PubMed ID: 22191486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotinylated polyacrylamide-based metal-chelating polymers and their influence on antigen recognition following conjugation to a trastuzumab Fab fragment.
    Liu P; Boyle AJ; Lu Y; Reilly RM; Winnik MA
    Biomacromolecules; 2012 Sep; 13(9):2831-42. PubMed ID: 22871127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
    Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
    Menendez JA; Vellon L; Mehmi I; Oza BP; Ropero S; Colomer R; Lupu R
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10715-20. PubMed ID: 15235125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
    Sharma R; Kameswaran M; Pandey U; Dash A
    J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.